User login
Key clinical point: Use of beta-adrenergic receptor blockers is associated with prolonged survival in patients with hepatocellular carcinoma (HCC).
Major finding: Beta-blocker use was associated with better overall survival (hazard ratio 0.69; P = .0031), with no significant heterogeneity across studies (I2 = 41%; P = .18).
Study details: The data come from a meta-analysis of 3 cohort studies involving 5148 patients with HCC that analyzed the association between the use of beta-blockers (including propranolol) and overall survival of the patients.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Chang H and Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: A systemic review and meta-analysis. Clin Exp Med. 2022 (Jun 23). Doi: 10.1007/s10238-022-00842-z
Key clinical point: Use of beta-adrenergic receptor blockers is associated with prolonged survival in patients with hepatocellular carcinoma (HCC).
Major finding: Beta-blocker use was associated with better overall survival (hazard ratio 0.69; P = .0031), with no significant heterogeneity across studies (I2 = 41%; P = .18).
Study details: The data come from a meta-analysis of 3 cohort studies involving 5148 patients with HCC that analyzed the association between the use of beta-blockers (including propranolol) and overall survival of the patients.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Chang H and Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: A systemic review and meta-analysis. Clin Exp Med. 2022 (Jun 23). Doi: 10.1007/s10238-022-00842-z
Key clinical point: Use of beta-adrenergic receptor blockers is associated with prolonged survival in patients with hepatocellular carcinoma (HCC).
Major finding: Beta-blocker use was associated with better overall survival (hazard ratio 0.69; P = .0031), with no significant heterogeneity across studies (I2 = 41%; P = .18).
Study details: The data come from a meta-analysis of 3 cohort studies involving 5148 patients with HCC that analyzed the association between the use of beta-blockers (including propranolol) and overall survival of the patients.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Chang H and Lee SH. Beta-adrenergic receptor blockers and hepatocellular carcinoma survival: A systemic review and meta-analysis. Clin Exp Med. 2022 (Jun 23). Doi: 10.1007/s10238-022-00842-z